ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0692

The Interplay Between Lipid Peroxidation and Neutrophil Extracellular Trap (NET) Formation in APS Pathogenesis
Abstract Number: PP23

The Journey to Collaborative Care and Patient-Centric Educational Opportunities for a Scleroderma Patient
Abstract Number: 0369

The Longitudinal Measurement Properties and Clinical Application of the PROMIS Fatigue 13a and 10a in Lupus
Abstract Number: 1142

The Lupus Risk Allele Associated Xq28 Haplotype Identifies the Molecular Endotype of a Cohort of European SLE Patients with Enhanced IRAK1 Signaling
Abstract Number: 1712

The Lymph Node Microenvironment in SLE Mice Is Altered and Impairs Egress of T Lymphocytes
Abstract Number: 2221

The Molecular Endotypes of Type 1 and Type 2 SLE
Abstract Number: 0696

The Mortality Trends Related to SLE in the United States – A 20-year Analysis (2001-to 2020) from the WONDER Database
Abstract Number: 1389

The New Serum Synovial Biochemical Marker HELIX-III Predicts Radiological Progression in Early Arthritis Independently of Usual Risk Factors
Abstract Number: 0042

The Pathogenic Role of Lymphatic Vessels in Autoimmune Valvular Carditis
Abstract Number: 0789

The Persistence of Anti-Spike Antibodies Following Two SARS-CoV-2 Vaccine Doses in Patients with Immune-mediated Inflammatory Diseases on Immunosuppressive Therapy Compared to Healthy Controls: A Prospective Cohort Study
Abstract Number: 0690

The Physiological Ketone Body Beta-Hydroxybutyrate Potently Neutralizes APS-Associated NETosis
Abstract Number: 1969

The Potential Diagnostic Value of C-X-C Motif Chemokine 13 (CXCL13) in Seronegative Arthritis
Abstract Number: 1685

The Presence of Anti-MAA Antibodies to Extracellular Matrix Proteins in Synovial Fluid and Sera of Patients with Rheumatoid Arthritis
Abstract Number: 0375

The Presence of Heel Enthesitis on Physical Exploration Is Associated with Poorer Outcomes After 2 Years of Follow-up in Patients with Radiographic Axial Spondyloarthritis
Abstract Number: 1532

The Primary Cardiomyopathy of Systemic Sclerosis on Cardiovascular Magnetic Resonance Imaging

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].